Real-World Data Show Strong Early Responses to CAR-T Therapy in Hard-to-Treat Chronic Lymphocytic Leukemia

Real-world data presented at the 2026 Transplantation and Cellular Therapy (TCT) Meetings offer genuinely encouraging news for patients with heavily pretreated chronic lymphocytic leukemia (CLL): a retrospective, multi-institutional analysis of lisocabtagene maraleucel (liso-cel, brand name Breyanzi) — a CD19-directed CAR-T cell therapy — found high response rates and strong early survival in a population of patients who had already run out of standard options. This article walks through what the data actually showed, how it compares to the therapy's original pivotal trial, and what real caveats still apply.

What the Study Found

The analysis, known as the CARE CAR-T CLL study, pooled outcomes from 41 evaluable patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) treated with liso-cel across 19 U.S. treatment centers. This was a demonstrably difficult-to-treat population: the median age was 68, 95% of patients had already received at least three prior lines of therapy, 90% had previously been treated with pirtobrutinib (Jaypirca, a BTK inhibitor), and 63% carried high-risk TP53 abnormalities (deletion 17p or a TP53 mutation) — genetic features long associated with poor responses to standard CLL treatment. Despite that, the overall response rate was 85% (35 of 41 patients), with a confirmed complete response rate of 44%, rising to a combined rate of 56% when near-complete responses were included. The median time to reach the best response was just 30 days.

Survival and Safety

At a median follow-up of 3.3 months, 92% of patients remained progression-free at six months, and 88% were alive at six months overall — reaching 100% among those who achieved a complete response. Only one patient had relapsed by the data cutoff. Side effects were largely consistent with liso-cel's known safety profile and, encouragingly, skewed toward the milder end: cytokine release syndrome was grade 1 or 2 in the large majority of patients, with no grade 4 or 5 cases reported, and neurologic toxicity (ICANS) followed a similar pattern. Three patients did develop a serious hemophagocytic lymphohistiocytosis (HLH)-like syndrome, a known and serious potential complication of CAR-T therapy, and one of those cases was fatal — a sobering reminder that even strong real-world results carry real risk.

How This Compares to the Original Pivotal Trial

These real-world numbers look notably stronger than liso-cel's registrational trial, TRANSCEND CLL 004, which reported a 44% overall response rate and a 20% complete response rate with liso-cel alone in 65 patients (a combination of liso-cel with ibrutinib performed better in that trial, reaching an 86% overall response rate and 45% complete response rate). The investigators who presented the real-world data suggested a likely explanation: 98% of the real-world patients received bridging therapy before their CAR-T infusion, and 76% had a BTK inhibitor as their most recent treatment immediately beforehand — meaning many patients entered the CAR-T procedure with lower disease burden than typical pivotal-trial participants, which plausibly boosted response rates. When the researchers compared outcomes by specific bridging strategy, none of the differences reached statistical significance, underscoring that this remains an observational, hypothesis-generating analysis rather than a controlled comparison.

What It Means, and What's Still Uncertain

For patients who have exhausted multiple prior CLL treatments, including BTK inhibitors and other targeted therapies, a cell therapy that can still produce a complete response in close to half of a high-risk, heavily pretreated group is a genuinely meaningful result — real-world evidence that liso-cel's benefit extends into exactly the kind of difficult patient population oncologists most need better options for. That said, this is a small, retrospective analysis of 41 patients with a median follow-up of just over three months, far short of the 21-plus months reported in the pivotal trial, so how durable these responses will prove to be over one, two, or more years is genuinely unknown. The confidence intervals around subgroup comparisons were wide and crossed the line of no effect, meaning the exact role bridging therapy played can't yet be pinned down with statistical confidence. CAR-T therapy also remains available only at specialized treatment centers equipped to manage its distinct toxicities, including the kind of serious HLH-like complication seen in this cohort.

Bottom Line

Early real-world data on liso-cel in heavily pretreated, high-risk CLL are genuinely promising — high response rates, a fast time to response, and encouraging six-month survival in patients who had few remaining options. But this is a small, short-follow-up, retrospective analysis, not a randomized confirmation, and it included one serious treatment-related death. Longer follow-up from this and other real-world cohorts will be needed to know how durable these early responses really are.